Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer

著者: Rebecca Dent, Mafalda Oliveira, Steven J. Isakoff, Seock‐Ah Im, Marc Espié, Sibel Blau, Antoinette R. Tan, Cristina Saura, Matthew Wongchenko, Na Xu, Denise Bradley, Sarah-Jayne Reilly, Aruna Mani, Sung‐Bae Kim, on behalf of the LOTUS investigators, K. S. Lee, Joohyuk Sohn, Jong Hoon Kim, Jae Hong Seo, J.-S. Kim, S. Park, Michel Velez, Shaker R. Dakhil, Sara A. Hurvitz, Vicente Valero, Gregory A. Vidal, Robert A. Figlin, Mary Ann Allison, David Chan, Melody Cobleigh, Vincent Hansen, Nicholas Iannotti, W Lawler, Mohamad Salkini, L. Seigel, Gilles Romieu, Marc Debled, Christelle Lévy, A-C. Hardy-Bessard, Séverine Guiu, L. Garcia Estevez, Ruben D. Villanueva, Antonio González-Martı́n, Pedro Sánchez‐Rovira, Alfredo Montaño, M. I. Calvo Plaza, José Á. García-Sáenz, Isabel Garau, B. Bermejo, E. Vega Alonso, Hao‐Chien Wang, C.-S. Huang, Shyr‐Chyr Chen, Yen‐Hsu Chen, Ling-Ming Tseng, A. Wong, Christine Ang, Michelino De Laurentiis, PierFranco Conte, Filippo de Braud, Filippo Montemurro, L. Gianni, Luc Dirix - Breast Cancer Research and Treatment 2021 被引用: 74